VAR2 PHARMACEUTICALS ApS: Financial statements 2019
CVR: 34621942
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
VAR2 PHARMACEUTICALS ApS (CVR 34621942) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -4,729,732 and a net result of DKK -6,850,804 compared with DKK -3,967,644 the year before. Equity in the 2019 report amounted to DKK 48,290,470. The solvency ratio was 94.5%. The company had 8 employees in the financial year.
- Gross Profit
- DKK -4,729,732
- Profit/Loss
- DKK -6,850,804
- Equity
- DKK 48,290,470
- Total Assets
- DKK 51,105,821
- Employees
- 8
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -4.7 mio. | -6.9 mio. | 48.3 mio. | 8 |
| 2018 | - | -1.9 mio. | -4 mio. | 55.1 mio. | 6 |
| 2017 | - | -4 mio. | -4.4 mio. | 13.7 mio. | 3 |
| 2016 | - | -1.6 mio. | -1.9 mio. | 9.9 mio. | - |
| 2015 | - | -654 t. | -770 t. | 3.5 mio. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
VAR2 PHARMACEUTICALS ApS has published its annual report for 2018. Gross profit came to DKK -1,944,893, and the net result was DKK -3,967,644.
As of May 18, 2019, Mai-Britt Zocca has left the board of directors of VAR2 PHARMACEUTICALS ApS.
About VAR2 PHARMACEUTICALS ApS
VAR2 PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ali El-Salanti and Mads Daugaard. The board consists of Mads Daugaard (chair), Ali El-Salanti, Josef Rainer and Peter Schröcksnadel. The company is owned by ONCOMAL ApS and Københavns Universitet. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -21,739,014 and a net result of DKK -19,726,508 compared with DKK -21,006,013 the year before. Equity in the 2025 report amounted to DKK 82,032,248.